Race Receives $5.25m RD Tax Refund for Financial Year 2024
Filed with ASX · · 2 pages · English
Summary by 6ix AI
The company also received a positive determination regarding eligibility for overseas R&D activities, which extends the tax rebate to eligible activities conducted outside Australia. CEO Dr. Daniel Tillett emphasized the importance of this incentive for biopharmaceutical companies in addressing unmet patient needs and advancing clinical development.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Racura Oncology
- Race Submits Human Ethics for RC220 Phase 1 Trial
- Race Discovers Multiple Novel FTO Inhibitor Candidates
- Race Oncology Board Renewal Update
- Bisantrene Phase 2 AML Trial Successful Concludes
- RC220 GLP Non-clinical Toxicology Program Successful
Later from Racura Oncology
- Quarterly Activity Report and Appendix 4C
- Race Signs Contract for Phase 1 Trial of RC220
- S&P DJI Announces March 2025 Quarterly Rebalance
- Ethics approval received for RC220 Phase 1 Trial
- Race Initiates First AU Site for Phase 1 Solid Tumour Trial
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology